<DOC>
	<DOCNO>NCT01438060</DOCNO>
	<brief_summary>The primary objective study compare efficacy aripiprazole placebo patient psychosis associate Alzheimer 's dementia .</brief_summary>
	<brief_title>Aripiprazole Treatment Patients With Psychosis Associated With Dementia Alzheimer 's Type</brief_title>
	<detailed_description>Open label Extension Phase : The 130-week Extension Phase conduct provide information regard long-term safety efficacy aripiprazole participant diagnose onset Acute Phase psychotic symptom associate dementia Alzheimer 's type respond treatment 10-week Acute Phase study . Treatment beyond 140 week : A country-specific amendment France , allow participant treated aripiprazole , accord investigator 's opinion , show improvement Week 140 visit continue treatment beyond 140 week . The termination determine clinical benefit participant . Study design : Acute Phase : Randomized , double-blind , placebo-controlled , flexible-dose , parallel-group study . Extension Phase : Open label ; flexible-dose .</detailed_description>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>Noninstitutionalized patient diagnosis Alzheimer 's disease define Diagnostic Statistical Manual Mental Disorders Fourth Edition ( DSMIV ) criterion symptom delusion hallucination , present , least intermittently one month longer Mini Mental State Examination ( MMSE ) score 6 24 point Patients capable self locomotion locomotion aid assistive device Patients identify caregiver proxy For Extension Phase : Eligible patient male female complete 10week Acute Phase either treatment group ; Week 10 Total Score â‰¥ 6 NPI ; , judgment investigator , deem suitable participation longterm trial . Treatment beyond 140 week : All subject complete extension phase CN138006 French Investigational Site may consider eligible entry longer receive clinical benefit , per investigator 's judgment Patients Axis I ( DSM IV ) diagnosis : delirium amnestic disorder bipolar disorder schizophrenia schizoaffective disorder mood disorder psychotic feature Patients reversible cause dementia Patients psychotic symptom continuously present since prior onset symptom dementia Patients psychotic symptom well account another general medical condition direct physiological effect substance Patients current major depressive episode psychotic symptom hallucination delusion Patients diagnosis dementia relate infection human immunodeficiency virus Patients substanceinduced persistent dementia Patients dementia due vascular cause , multiinfarct , head trauma , Pick 's disease , Parkinson 's disease , frontal temporal dementia , Lewy body dementia , specific nonAlzheimer 's type dementia Patients seizure disorder Patients refractory neuroleptic use treat psychotic symptom past treated adequate period therapeutic dose , unless permission obtain BristolMyers Squibb Patients meet DSMIV criterion significant substance use disorder within 6 month prior start screen</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>